B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities

B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Exact query	Computed	Source
All time	… → 2026-09-15	`("B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities"[tiab])`	2026-09-15	pubmed
Last 5 years	2021-01-01 → 2026-12-31	`("B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-15	pubmed
Last 12 months	2025-09-15 → 2026-09-15	`("B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities"[tiab]) AND (2025/09/15:2026/09/15[dp])`	2026-09-15	pubmed

Data updated 16 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (44)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–44 of 44 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.
· Haematologica · 2021 · PMID 34196168 · validated civic_curation pubmed
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.
· Cancer Gene Ther · 2022 · PMID 35022522 · validated civic_curation pubmed
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
· J Clin Oncol · 2013 · PMID 23835704 · validated civic_curation pubmed
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.